Professor David Allsup's Projects (14)

Endometriosis and bleeding disorders: detection of endometriosis and identification of new treatment strategies Sep 1, 2024 - Aug 31, 2025
Endometriosis is a chronic, debilitating gynaecological disease that affects 1 in 10 women worldwide. In the UK the average wait for a diagnosis of endometriosis is 8 years which has not improved in over a decade. Due to the lack of an accurate non-... Read More about Endometriosis and bleeding disorders: detection of endometriosis and identification of new treatment strategies.

Prospective assessment of the fungal microbiome in persons with leukaemia Oct 1, 2024 - Sep 30, 2025
Fungal infections are an infreqeuent but severe complication of acute leukaemia treated with intensive chemotherapy. The current standard of care to prevent such infections is the prophylactic administration of antifungal drugs to persons with acute... Read More about Prospective assessment of the fungal microbiome in persons with leukaemia.

EPIC - NIS in CLL patients treated with acalabrutinib through the EAP Nov 1, 2023 - Nov 30, 2028

Supportive Care for Persons with Blood Cancers Nov 1, 2023 - Oct 31, 2028
The clinical haematology department is strongly committed to the development of the next generation of researchers, especially those with a commitment to the local area. We believe that improvements in the care provided for individuals with blood can... Read More about Supportive Care for Persons with Blood Cancers.

: A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients Oct 1, 2023 - Apr 1, 2025
A new mechanism has been identified where an intracellular switch, called AMP-activated protein kinase (AMPK) inhibits the function of constitutively active JAK2V617F protein responsible for disease in many patients with MPNs. Based on this observati... Read More about : A Targeted Approach To Reduce Risk of Blood Clotting in MPN Patients.

Identification of Fungal Microbiome Signatures in Patients with Blood Cancers Treated in the BioDrive AFS study Feb 1, 2023 - Jan 31, 2027

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314) Apr 1, 2023 - Apr 30, 2025
Commercial phase III randomised controlled trial conducted on behalf of Eli Lilly and Company in Hull University Teaching Hospital.
Dr Allsup is the local principal investigator in his capacity as honorary NHS consultant.

UoH finance team to liai... Read More about A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314).

LOXO BTK20020 (BRUIN CLL-321): A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL321) Aug 1, 2021 - Jul 31, 2025

The Biomarker Driven Antifungal Stewardship in AML: The BioDriveAFS Trial Sep 1, 2021 - Feb 28, 2026
NIHR commisioned bid for Antifungal Stewardship in Haemato-oncology.

https://www.nihr.ac.uk/documents/2026-antifungal-stewardship-in-haemato-oncology/24460

B-More: A 24-month prospective, non-interventional, international, multicentre study to describe the real-world effectiveness and usage of Alprolix in patients with haemophilia B in selected European and Middle Eastern countries Sep 1, 2019 - Dec 31, 2022
A phase IV multicentre, international study investigating the real-world efficacy of Alprolix, an extended half-life factor IX concentrate, in the management of haemophilia B.

Matrix Metalloproteinase Activated Multimodal 'Theranostic' Drug Delivery Imaging Agents For Thrombosis Mar 1, 2020 - Aug 31, 2024

STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) Jan 1, 2021 - Mar 31, 2031
Chronic lymphocytic leukaemia (CLL) is a cancer that affects the blood and bone marrow. It tends to progress slowly, and is incurable. CLL is the most common leukaemia in adults. The first treatment for CLL is chemotherapy. This is usually given for... Read More about STATIC: A Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL).

CLL Research Jan 26, 2015 - Dec 31, 2028
Translational research project utilising prospective sample collection from patients attending the Haematology Clinic, Hull university Teaching Hospital Trust, to facilitate research within the University of Hull.

LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy Jun 1, 2018 - Feb 28, 2022
Acute leukaemia (AL) is an aggressive but potentially curable cancer that can affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking the mother’s survival through... Read More about LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy.